Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GYKCF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
H01L02-ADC
|
|||||
| Synonyms |
H01L02-ADC
Click to Show/Hide
|
|||||
| Organization |
DAIICHI SANKYO COMPANY, LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CDH6 mAb H01L02
|
Antibody Info | ||||
| Antigen Name |
Cadherin-6 (CDH6)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.0572 nM | High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab1 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||